Clinical Trials Directory

In this study, people will take a medicine called S241656 by mouth. They may take it by itself or with other cancer treatments, and they may take it once or twice a day depending on their study group. The study has two parts. In Part 1, people receive different amounts of the medicine so researchers can find the safest dose. In Part 2, people receive the safest dose that was found in Part 1. Participants will keep taking the medicine until their cancer gets worse or the side effects become too strong or happen too often. During the study, they will visit the clinic regularly and have many tests, including blood tests, urine tests, and scans. The whole study is expected to last about five years.

In this study, participants will complete two or three in-person visits where they answer surveys and walk for six minutes. After that, they will be placed into one of two groups. One group will start the exercise and nutrition program right away, and the other group will start the program later. The program lasts for twelve weeks. During this time, there will be classes three times each week that last one hour. There will also be a nutrition session every other week. Participants do not need to attend every session, but they are asked to come to at least two thirds of the classes.

This study wants to see how well two tests—called PCCT and ultrasound—can find fat and scars in the liver. To check if they work, doctors will compare them to another test called an MRI, which is known to be very good.

We are doing this study to learn more about the connection between the brain and leg muscles in people who have chronic stroke. We want to understand how this connection affects the walking abilities of chronic stroke patients so we can provide better help to stroke patients who need to improve their motor function.

People in this study will be placed into one of three groups based on their brain condition. During their planned brain surgery, doctors will collect a small sample of bone marrow from the skull and a small sample of blood. This will happen only one time while the patient is fully asleep under anesthesia. The sample will be taken during the surgery and should not make the operation much longer. There is no study medicine or device. The only part of the study is the one-time sample collection. Patients can choose to stop being in the study at any time, even before or after the sample is taken.

We are doing this study to find out if an experimental drug called PT217 (the study drug) is a safe and effective option for people who have neuroendocrine carcinomas. We want to see how this drug works when it is given on its own and in combination with standard chemotherapy and/or immunotherapy drugs.

We are doing this study to find out if a new type of assessment works well for middle-aged and older adults with sickle cell disease (SCD). We want to see if this assessment is useful in detecting changes in health. We hope the assessment can provide useful information to help improve the quality of life for adults with sickle cell disease.